LY-3437943 · 30 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
Retatrutide 30 mg kit
Triple-receptor agonist — 30 mg vial, full research kit.
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.
What the peptide is.
Retatrutide (LY-3437943) is an investigational triple-agonist peptide being studied in Phase 3 trials. The 30 mg vial is the mid-dose presentation, widely used in extended research protocols and analytical-chemistry reference work.
Every lot is tested by Janoshik Analytical in Slovakia: HPLC for purity, ESI-MS for identity. COA is published on the product page before the lot lists for sale.
Simultaneous agonism at GLP-1, GIP, and glucagon receptors. The added glucagon-receptor agonism is proposed to drive energy-expenditure effects in addition to incretin-mediated insulin secretion.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Amber glass vial, argon-purged headspace, butyl stopper.
- ▸Do not refreeze reconstituted solution.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT Retatrutide 30 mg kit
DESIGNATION LY-3437943
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.20
MASS EXP. 4729.40 Da
MASS OBS. 4729.42 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Registered clinical investigation.
Links below resolve to the ClinicalTrials.gov registry. Trial status reflects publicly disclosed information at the time of publication.
| NCT | Phase | Title | Status | |
|---|---|---|---|---|
| NCT05929066 | Phase 3 | TRIUMPH-1: Retatrutide in obesity | Ongoing | Registry ↗ |
Research references for Retatrutide 30 mg kit.
2 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Jastreboff AM, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial
NEJM · 2023 - [02]Rosenstock J, et al.
Retatrutide in people with type 2 diabetes — Phase 2
The Lancet · 2023
- Q.How does this differ from the 40 mg pen?
- A.Same active peptide. The vial kit is lyophilised and requires reconstitution (bac water and syringes included); the pen is pre-filled and shipped cold-chain. Vial kits have a longer shelf life and do not require cold-chain shipping.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
Retatrutide 40 mg pen
Triple-receptor agonist — pre-filled research pen, 4 × 10 mg.
- Form
- Pre-filled pen
- Dose
- 40 mg / 3 mL pen
- Purity
- ≥ 99.2%
Retatrutide 10 mg kit
Triple-receptor agonist — 10 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.2%
Cagrilintide 10 mg
Long-acting amylin analogue — GLP-1 stack partner.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 98.5%